CHMP meeting highlights – December 2022
European Pharmaceutical Review
DECEMBER 19, 2022
The group adopted a positive opinion for Tremelimumab AstraZeneca (tremelimumab), to treat metastatic non-small cell lung cancer (NSCLC) in combination with Imfinzi (durvalumab) and platinum-based chemotherapy. EMA human medicines committee (CHMP) highlights, November 2022.
Let's personalize your content